High CLL Remission Seen With First-Line Triplet Regimen Nancy A. Melville September 15, 2026

https://www.medscape.com/viewarticle/high-cll-remission-seen-first-line-triplet-regimen-2026a1000y5j?src= Outcomes were positive, but toxicities were concerning in patients with chronic lymphocytic leukemia (CLL) treated with a combination of the noncovalent Bruton tyrosine kinase inhibitor (BTKi) pirtobrutinib with venetoclax and obinutuzumab in the first-line setting.